“2024 was a year of significant advancements across several areas,” stated Jacob Chacko, M.D., president and chief executive officer. “Key achievements included initiation of multiple cohorts for ORIC-114 in non-small cell lung cancer and ORIC-944 in metastatic castration-resistant prostate cancer. We also established three strategic partnerships with major pharmaceutical companies, expanded our leadership team’s expertise, and secured $125 million in financing, which extends our cash runway into late 2026. We anticipate seven data readouts in the next year and a half and are working towards potential registration studies for ORIC-114 in the latter half of 2025 and for ORIC-944 in early 2026.”
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Buy Rating on Oric Pharmaceuticals: Capitalizing on Prostate Cancer Treatment Advances
- Oric recent weakness a buying opportunity, says JPMorgan
- Promising Efficacy and Manageable Safety of ORIC-944 Positions ORIC Shares Favorably
- Positive Outlook for Oric Pharmaceuticals Driven by Promising Trial Results of Mevrometostat and Xtandi Combination
- Oric Pharmaceuticals: Promising Trials and Strong Financials Justify Buy Rating